Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha neutrophils therapy - LIfT Biosciences

Next Previous
Drug Profile

Alpha neutrophils therapy - LIfT Biosciences

Alternative Names: IMAN (iPSC) - LIfT BioSciences; Induced pluripotent stem cell derived neutrophil based leukocyte infusion therapy - LIfT Biosciences

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LIfT Biosciences
  • Class Antineoplastics; Immunotherapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Leukocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 22 May 2025 Pharmacodynamics data from a preclinical trial in Solid tumours released by LIfT Biosciences
  • 19 May 2025 Pharmacodynamics data from a preclinical study in Solid tumours released by LIfT Biosciences
  • 28 Apr 2025 LIfT BioSciences in collaboration with University of Galway plans to initiate a phase-I trial (Monotherapy, Combination therapy, Second-line therapy or greater) for the treatment of solid tumours in 2026, pending final regulatory approvals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top